Background
Panitumumab with trade name Vectibix, is an FDA-approved drug for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. It is a human monoclonal antibody. Panitumumab binds to the human EGF receptor (EGFR), preventing binding of activating ligands, such as the EGF and transforming growth factor-α. Antibodysystem Anti-Panitumumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Panitumumab.• Multiplexed evaluation of a cell-based assay for the detection of antidrug neutralizing antibodies to panitumumab in human serum using automated fluorescent microscopy., PMID:20508254